NEW YORK (GenomeWeb) – The US Food and Drug Administration has granted Cepheid clearance to market the Xpert Carba-R test, the firm announced today.

According to the company, it is the first FDA-cleared test to detect and differentiate carbapenemase genes in pure bacterial isolates that were previously determined to be non-responsive to carbapenem antibiotics, considered the last line of defense to treat infections. The test identifies 5 families of carbapenem resistance genes in carbapenem-producing organisms (CPOs), including KPC, NDM, VIM, OXA-48, and IMP.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.